Despite science’s best efforts, rare diseases remain far too common. It’s time to tackle the undone, the too difficult, and the inaccessible…
Location: United States, Connecticut, New Haven
Employees: 11-50
Total raised: $182M
Founded date: 2018
Investors 8
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.05.2020 | Series B | $145M | - |
| 26.04.2018 | Series A | $37M | - |
Mentions in press and media 19
| Date | Title | Description |
| 28.10.2024 | Be Biopharma: Pioneering the Future of Genetic Medicine with $82 Million in New Funding | In the ever-evolving landscape of biotechnology, Be Biopharma stands out like a lighthouse in a storm. This Cambridge, Massachusetts-based company has just secured $82 million in funding, a financial windfall that promises to propel its inn... |
| 25.10.2024 | Be Bio: $82 Million Raised To Discover And Develop Engineered B Cell Medicines | Be Biopharma – a leader in the discovery and development of engineered B Cell Medicines (BCMs) – announced key milestones alongside a new round of funding as its lead program BE-101 for Hemophilia B, enters the clinic, and its second develo... |
| 11.11.2022 | Rallybio Announces Pricing of $50 Million Public Offering | Rallybio Corporation ("Rallybio") RLYB today announced the pricing of an underwritten public offering of 5,000,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain inve... |
| 07.11.2022 | Affibody’s partner Rallybio Announces Positive Phase 1 Results for RLYB116 | Affibody’s partner Rallybio Announces Positive Phase 1 Results for RLYB116 Mon, Nov 07, 2022 22:08 CET Report this content • A single 100 mg subcutaneous dose demonstrated a reduction of >99% in free C5 and was generally well-tolerated. ... |
| 22.07.2021 | Rare disease biotech Rallybio sets terms for $81 million IPO | - |
| 12.07.2021 | Rallybio hits high gear as it targets $100M IPO to fund treatments for rare fetal bleeding disorder | - |
| 19.05.2020 | Rallybio scores $145M, unveils lead rare disease program | - |
| 19.05.2020 | Rallybio Scoops Up $145M Series B Round | NEW HAVEN, CT, Rallybio today announced the completion of a $145 million Series B financing. >> Click here for more funding data on Rallybio >> To export Rallybio funding data to PDF and Excel, click here Rallybio, a biop... |
| 19.05.2020 | Rallybio Completes $145 Million Series B | NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the completion of... |
| 19.05.2020 | Rallybio scores $145M, unveils lead rare disease program | When a trio of Alexion veterans started Rallybio, they vowed to take an “agnostic” approach to new medicines, because “diseases have no boundaries, so why should we?” Two years later, they’ve raised $145 million to bankroll a pipeline of ea... |
Show more